While liquid biopsies are a valuable, less invasive tool, a negative result is inconclusive for ruling out actionable mutations in NSCLC. It may simply mean the tumor isn't shedding enough DNA. Therefore, a negative liquid biopsy should never be the final word; it must be followed by a tissue biopsy to ensure patients don't miss out on targeted therapies.

Next-generation mutant-specific PI3K inhibitors could lead to complex biomarker requirements. A future drug label might require a PIK3CA mutation for eligibility but simultaneously exclude patients who also have downstream PTEN or AKT alterations, which can confer resistance.

Dr. Wander favors liquid biopsies for tracking disease progression because they are safer and easier for patients. While acknowledging that tissue biopsies can sometimes detect mutations missed by liquid ones (10-30% discordance), he believes rapidly advancing technology will soon minimize these discrepancies, making them the standard for monitoring.

Unlike invasive tissue biopsies that sample a single site, liquid blood biopsies provide a comprehensive, real-time snapshot of mutations across all metastatic sites. This is crucial for identifying acquired mutations and guiding timely treatment decisions.

Clinicians increasingly perform Next-Generation Sequencing (NGS) on initial diagnostic tissue, even if results don't alter first-line treatment. This proactive approach identifies stable mutations like PIK3CA early, enabling long-term planning, such as optimizing a patient's metabolic health in anticipation of future targeted therapies.

Clinicians must recognize that liquid and solid biopsies show significant discordance. ESR1 mutations are more frequently detected in liquid assays, while PIK3CA mutations are more often found in solid tissue. This variability by gene directly impacts the optimal testing strategy for patients.

Liquid biopsies are superior for ESR1 testing because the mutation is subclonal and develops under therapy pressure. A tissue biopsy from one metastatic site can miss the mutation, while circulating tumor DNA (ctDNA) from a blood sample aggregates genetic material from all sites, increasing detection rates.

Even with contemporaneously collected samples, biomarker concordance between solid tissue and liquid biopsies is not uniform. Data shows ESR1 mutations are consistently more likely to be discordant—often found only in liquid—than PIK3CA or AKT mutations, reinforcing the need for gene-specific testing strategies.

Despite the risk of missing mutations, oncologists predominantly use convenient, less-invasive liquid biopsies to test for biomarkers at disease progression. A more invasive tissue biopsy is generally reserved for situations where the cancer behaves unexpectedly, such as a sudden shift from bone-only to visceral disease, which might suggest a missed biological driver.